HARROW EYE
Big PharmaHARROW EYE is a major pharmaceutical company focused on Ophthalmology, Infectious Disease, Dermatology. Key products include ILEVRO.
HARROW EYE's Key Drugs
HARROW EYE's core commercial portfolio centers on ILEVRO, BYQLOVI, TYRVAYA, spanning Ophthalmology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Pain
Inflammation
Dry Eye Disease
Allergic Conjunctivitis
Dry Eye Disease
HARROW EYE's Recent FDA Approvals
New NDA/BLA approvals for HARROW EYE over the last two years — novel drugs only, excluding generics and label supplements.
HARROW EYE's Therapeutic Areas
HARROW EYE's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Infectious Disease, across 0 biologic and 16 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HARROW EYE's Top Competitors
HARROW EYE's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH AND LOMB INC, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HARROW EYE Pipeline Snapshot
Active clinical trials for HARROW EYE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ILEVRO leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling